Randomized proof from scientific trials and naturalistic evidence collected from pharmacoepidemiology and pharmacovigilance actions each contribute on the initial and continuous assessment in the benefits and risks of the drug, ie, the stability between therapeutic efficacy and safety risks. Benefit-risk assessment (BRA) largely relies on the quali